{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:53:00Z","timestamp":1760647980742,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polymorphic ventricular tachycardia (PMVT) is an unstable and often fatal cardiac tachyarrhythmia. While there are many causes of this rhythm, including electrolyte imbalances, ischemia, and genetic disorders, iatrogenic etiologies are important to recognize. Abiraterone is an androgen synthesis antagonist effective in treating prostate cancer, but here we describe a case of severe hypokalemia secondary to abiraterone resulting in polymorphic ventricular tachycardia and cardiac arrest. While this is a potential adverse effect of the medication, severe hypokalemia causing polymorphic ventricular tachycardia and cardiac arrest, as seen in our patient\u2019s case, has not been described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 78-year-old African-American man with history of prostate cancer presents with polymorphic ventricular tachycardia and cardiac arrest. After resuscitation, he was found to be severely hypokalemic and refractory to large doses of repletion. Evaluation of secondary causes of hypokalemia identified the likely culprit to be adverse effects from prostate cancer treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A broad differential diagnosis for polymorphic ventricular tachycardia is essential in identifying and treating patients presenting in this rhythm. Here we present a case of iatrogenic polymorphic ventricular tachycardia secondary to oncologic treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04513-3","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:02:11Z","timestamp":1713225731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Polymorphic ventricular tachycardia and cardiac arrest from abiraterone-induced hypokalemia: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Jessica","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison Komatsu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Komal","family":"Preet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nare","family":"Torosyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarmen","family":"Sarkissian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-1572","authenticated-orcid":false,"given":"Joseph","family":"Ebinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"4513_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/circulationaha.121.055783","volume":"144","author":"S Viskin","year":"2021","unstructured":"Viskin S, et\u00a0al. Polymorphic ventricular tachycardia: terminology, mechanism, diagnosis, and emergency therapy. Circulation. 2021;144:823\u201339. https:\/\/doi.org\/10.1161\/circulationaha.121.055783.","journal-title":"Circulation"},{"key":"4513_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, et\u00a0al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1704174.","journal-title":"N Engl J Med"},{"key":"4513_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/sj.bjc.6604904","volume":"100","author":"JE Ang","year":"2009","unstructured":"Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100:671\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6604904.","journal-title":"Br J Cancer"},{"key":"4513_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/cncr.31836","volume":"125","author":"RR McKay","year":"2019","unstructured":"McKay RR, et\u00a0al. A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer. 2019;125:524\u201332. https:\/\/doi.org\/10.1002\/cncr.31836.","journal-title":"Cancer"},{"key":"4513_CR5","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","volume":"5","author":"G Attard","year":"2019","unstructured":"Attard G, et\u00a0al. Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer: a randomized, open-label phase 2 study. JAMA Oncol. 2019;5:1159\u201367. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1011.","journal-title":"JAMA Oncol"},{"key":"4513_CR6","doi-asserted-by":"publisher","first-page":"1414395","DOI":"10.1155\/2018\/1414395","volume":"2018","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto Y, et\u00a0al. Serious hypokalemia associated with abiraterone acetate in patients with castration-resistant prostate cancer. Case Rep Urol. 2018;2018:1414395. https:\/\/doi.org\/10.1155\/2018\/1414395.","journal-title":"Case Rep Urol"},{"key":"4513_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12872-021-01945-3","volume":"21","author":"X Morales","year":"2021","unstructured":"Morales X, Garnica D, Isaza D, Isaza N, Dur\u00e1n-Torres F. Syncope due to non-sustained episodes of Torsade de Pointes associated to androgen-deprivation therapy use: a case presentation. BMC Cardiovasc Disord. 2021;21:136. https:\/\/doi.org\/10.1186\/s12872-021-01945-3.","journal-title":"BMC Cardiovasc Disord"},{"key":"4513_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23678","volume":"14","author":"DH Lee","year":"2022","unstructured":"Lee DH, Money DB, Deshpande A, Samuels B. A case of abiraterone-related hypokalemia leading to torsades de pointes and cardiac arrest. Cureus. 2022;14: e23678. https:\/\/doi.org\/10.7759\/cureus.23678.","journal-title":"Cureus"},{"key":"4513_CR9","doi-asserted-by":"publisher","first-page":"ytab462","DOI":"10.1093\/ehjcr\/ytab462","volume":"5","author":"M Riad","year":"2021","unstructured":"Riad M, Allison JS, Nayyal S, Hritani A. Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report. Eur Heart J Case Rep. 2021;5:ytab462. https:\/\/doi.org\/10.1093\/ehjcr\/ytab462.","journal-title":"Eur Heart J Case Rep"},{"key":"4513_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1177\/10781552211015794","volume":"27","author":"L McBride","year":"2021","unstructured":"McBride L, Woronow D, Nayernama A, Christopher Jones S. Abiraterone acetate-associated QT prolongation and torsades de pointes: postmarketing cases reported to FDA. J Oncol Pharm Pract. 2021;27:1315\u20136. https:\/\/doi.org\/10.1177\/10781552211015794.","journal-title":"J Oncol Pharm Pract"},{"key":"4513_CR11","first-page":"124","volume":"129","author":"A Khan","year":"2016","unstructured":"Khan A, Kneale B. Life threatening torsades de pointes due to abiraterone-induced hypokaelemia in a patient with metastatic prostate cancer. N Z Med J. 2016;129:124\u20137.","journal-title":"N Z Med J"},{"key":"4513_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1060028014555362","volume":"49","author":"F Rodieux","year":"2015","unstructured":"Rodieux F, Nieto N, Sunthorn H, John G, Escher M. Abiraterone acetate-induced life-threatening torsade de pointes. Ann Pharmacother. 2015;49:152\u20133. https:\/\/doi.org\/10.1177\/1060028014555362.","journal-title":"Ann Pharmacother"},{"key":"4513_CR13","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/17843286.2018.1543827","volume":"74","author":"B Dhondt","year":"2019","unstructured":"Dhondt B, et\u00a0al. Abiraterone and spironolactone in prostate cancer: a combination to avoid. Acta Clin Belg. 2019;74:439\u201344. https:\/\/doi.org\/10.1080\/17843286.2018.1543827.","journal-title":"Acta Clin Belg"},{"key":"4513_CR14","doi-asserted-by":"publisher","first-page":"e599","DOI":"10.1016\/j.clgc.2016.12.008","volume":"15","author":"D Gill","year":"2017","unstructured":"Gill D, et\u00a0al. Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration-resistant prostate cancer treated with abiraterone without prednisone. Clin Genitourin Cancer. 2017;15:e599\u2013602. https:\/\/doi.org\/10.1016\/j.clgc.2016.12.008.","journal-title":"Clin Genitourin Cancer"},{"key":"4513_CR15","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","volume":"16","author":"R Iacovelli","year":"2018","unstructured":"Iacovelli R, et\u00a0al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16:e645\u201353. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.007.","journal-title":"Clin Genitourin Cancer"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04513-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:02:43Z","timestamp":1713225763000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04513-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4513"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04513-3","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"31 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}